News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Phase 2 Clinical Trial Site in London, UK Now Enrolling Children
Clementia is pleased to announce that its clinical trial site at The Royal National Orthopaedic Hospital in London, England is now ready to enroll children age 6 to 14 who meet the study eligibility criteria. This site joins the University of California San Francisco (UCSF) and the Necker
View HTML
Toggle Summary Clementia Clinical Program Update: Clementia Phase 2 Clinical Trial Site in Paris, France Now Enrolling Children
MONTREAL, CANADA, October 8, 2015  – Clementia is pleased to announce that its clinical trial site at Hôpital Necker-Enfants Malades in Paris, France is now ready to enroll children age 6 to 14 who meet the study eligibility criteria. This site joins the University of California San Francisco
View HTML
Toggle Summary Palovarotene Phase 2 Study Milestone
MONTREAL, CANADA, September 28, 2015  –  Clementia Pharmaceuticals Inc.  (Clementia) announces the completion of enrollment of adults (age 15 years and older) into the Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva.
View HTML
Toggle Summary Clementia Pharmaceuticals Expands Ongoing Phase 2 Study to Include Children with Fibrodysplasia Ossificans Progressiva (FOP)
Additional Clinical Trial Site Opens in UK MONTREAL, CANADA, August 25, 2015  –  Clementia Pharmaceuticals Inc.  today announced the initiation of enrollment of children as young as 6 years old in the company’s ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia
View HTML
Toggle Summary Clementia Pharmaceuticals Raises U.S. $60 Million in Mezzanine Financing to Support Development of Palovarotene for Fibrodysplasia Ossificans Progressiva
Names Michael Singer Chief Financial Officer MONTREAL, CANADA, June 23, 2015  –  Clementia Pharmaceuticals Inc.  today announced the completion of a U.S. $60 million mezzanine round of financing to support the ongoing development of the Company’s lead compound palovarotene for the
View HTML
Toggle Summary Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva
Study Now Enrolling Patients Ages Two through 65 Years Old MONTREAL, CANADA, May 28, 2015  –  Clementia Pharmaceuticals Inc.  today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patientswith fibrodysplasia ossificans
View HTML
Toggle Summary Clementia Pharmaceuticals Joins Global Patient Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day
MONTREAL, CANADA, April 23, 2015  –  Clementia Pharmaceuticals Inc.  today joins patients, their families, patient organizations and the scientific community in recognizing and supporting Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 2015.
View HTML
Toggle Summary Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia Ossificans Progressiva Based on Recommendations from Data Monitoring Committee (DMC)
MONTREAL, CANADA, APRIL 2, 2015  –  Clementia Pharmaceuticals Inc.  announced today that the Data Monitoring Committee (DMC) for the company’s Phase 2 adaptive‐design, dose‐ranging study of palovarotene for fibrodysplasia ossificans progressiva (FOP) has completed a planned review of
View HTML
Toggle Summary Clementia Pharmaceuticals Highlights Role of Patient Community in the Fight Against Fibrodysplasia Ossificans Progressiva (FOP)
Company to Host Webcast to Pay Tribute to FOP Community and Recognize Rare Disease Day MONTREAL, CANADA, February 24, 2015  –  Clementia Pharmaceuticals Inc.  will observe Rare Disease Day 2015 by hosting a webcast to commend patients and caregivers for their role in advancing basic
View HTML
Toggle Summary Clementia Completes Enrollment Of First Cohort In Phase 2 Clinical Trial!
Clementia is pleased to announce the enrollment of the 8th patient in Cohort 1 of its Phase 2 clinical trial of palovarotene for the treatment of FOP! This important milestone triggers the Data Monitoring Committee (DMC) review after this 8th patient completes the 42-day treatment period.
View HTML